Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...

Founded in 2011 under the name M3 Biotechnology, Athira has been trying to develop small molecule drugs that help regenerate ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...

Baldanza has largely kept a low profile aside from co-hosting a podcast on aviation since his sudden resignation in 2016. The ...

Indivior PLC the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years ...

Ben Baldanza, who was perhaps best known in the aviation world for helping to pioneer discount air travel at the US's Spirit Airlines, has died aged 62. An obituary has been posted on Baldanza’s ...

Denali has two wholly-owned, late-stage development programs — DNL310 for (Hunter syndrome) and DNL343 (eIF2B activator) — for amyotrophic lateral sclerosis (ALS). DNL310, or tividenofusp alfa, is an ...

Neurosense Therapeutics (NASDAQ:NRSN) is developing novel treatments for neurodegenerative diseases like amyotrophic lateral ...